Zenas BioPharma Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
ZBIO$28.57+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, · · December 31, | ||||||
| · 2024 · 2023 | ||||||
| Assets · · · · · | ||||||
| Current assets: | | | | | | |
| Cash and cash equivalents | | $319,742 | | $56,857 | ||
| Short-term investments | | | 31,024 | | | — |
| Restricted cash | | | 90 | | | — |
| Prepaid expenses and other current assets | | | 5,067 | | | 2,947 |
| Total current assets | | | 355,923 | | | 59,804 |
| Property and equipment, net | | | 185 | | | 193 |
| Operating lease right-of-use assets, net | | | 1,004 | | | 821 |
| Restricted cash | | | — | | | 86 |
| Other non-current assets | | | 12,856 | | | 7,276 |
| Total assets | | $369,968 | | $68,180 | ||
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit) | | | | | | |
| Current liabilities: | | | | | | |
| Accounts payable (includes $560 and $21 owed to related parties, respectively) | | $17,136 | | $5,396 | ||
| Accrued expenses (includes $260 and $404 owed to related parties, respectively) | | | 39,371 | | | 17,306 |
| Operating lease liabilities, current | | | 785 | | | 556 |
| Total current liabilities | | | 57,292 | | | 23,258 |
| Operating lease liabilities, non-current | | | 218 | | | 257 |
| Convertible notes, at fair value | | | — | | | 20,300 |
| Total liabilities | | | 57,510 | | | 43,815 |
| Commitments and contingencies (Note 14) | | | | | | |
| Convertible preferred stock: | | | | | | |
| Series Seed convertible preferred stock, par value $0.0001 per share; 0 and 1,785,714 shares authorized, issued and outstanding as of December 31, 2024 and 2023, respectively. | | | — | | | 956 |
| Series A convertible preferred stock, par value $0.0001 per share; 0 and 17,589,380 shares authorized, issued and outstanding as of December 31, 2024 and 2023, respectively. | | | — | | | 55,840 |
| Series B convertible preferred stock, par value $0.0001 per share; 0 and 81,242,587 shares authorized, issued and outstanding as of December 31, 2024 and 2023, respectively. | | | — | | | 193,290 |
| Stockholders’ equity (deficit): | | | | | | |
| Preferred stock, par value $0.0001 per share; 25,000,000 and no shares authorized as of December 31, 2024 and 2023, respectively; no shares issued and outstanding as of December 31, 2024 and 2023. | | | — | | | — |
| Common stock, par value $0.0001 per share; 175,000,000 shares authorized as of December 31, 2024 and 2023; 41,793,412 and 1,576,854 shares issued and outstanding as of December 31, 2024 and 2023, respectively. | | | 4 | | | — |
| Additional paid-in capital | | | 699,651 | | | 4,645 |
| Accumulated other comprehensive income | | | 194 | | | 37 |
| Accumulated deficit | | | (387,391) | | | (230,403) |
| Total stockholders’ equity (deficit) | | | 312,458 | | | (225,721) |
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | | $369,968 | | $68,180 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.